The extent of the survival improvement was related to both the magnitude and duration of progerin reduction at low levels, demonstrating that the level of plasma progerin is a biomarker of HGPS that enables the short- and long-term assessment of progerin-targeted therapeutic efficacy through progerin reduction [35]. This evidence concerns the gene LMNA and Hutchinson-Gilford progeria syndrome.